Microglia Activation in Neurodegeneration
Overview
Microglia activation represents the innate immune response of the brain, playing a dual role in neurodegeneration—protective clearance of pathogens and debris versus chronic neuroinflammation that drives disease progression[@heneka2015]. These resident macrophages constitute 10-15% of brain cells and are critical in Alzheimer's disease ([AD](/diseases/alzheimers-disease)), Parkinson's disease ([PD](/diseases/parkinsons-disease)), and other neurodegenerative disorders[@prinz2014].
Microglia are unique immune cells of the central nervous system (CNS) that originate from embryonic yolk sac progenitors and self-renew locally throughout life[@ginhoux2013]. Unlike peripheral macrophages, microglia maintain their population through self-proliferation rather than continuous recruitment from bone marrow-derived monocytes[@ajami2007]. This self-renewal capacity is mediated by the colony-stimulating factor 1 receptor (CSF1R) signaling pathway, which has become a therapeutic target for modulating microglial abundance in disease states[@elmore2014].
The concept of microglial polarization has evolved significantly over the past decade. Initially described as a binary M1/M2 classification, current understanding recognizes microglia exist on a spectrum of activation states influenced by the local microenvironment[@ransohoff2016]. This spectrum includes surveillant (homeostatic), disease-associated microglia (DAM), and various intermediate phenotypes that can transition between states depending on pathological cues[@krasemann2017].
Microglia Development and Ontogeny
Embryonic Origin
Microglia arise from primitive macrophages in the embryonic yolk sac during early development (embryonic day 7-8 in mice)[@alliot1999]. This distinct ontogeny explains their unique transcriptional signature compared to peripheral myeloid cells[@kierdorf2013]. The transcription factor PU.1 (encoded by SPI1) is essential for microglial development, and conditional knockout results in complete absence of microglia in the adult brain[@schulz2012].
Key developmental transcription factors include:
- PU.1: Master regulator of myeloid cell fate
- IRF8: Controls microglial identity and gene expression
- CSF1R: Receptor for CSF1 and IL-34, required for survival and proliferation
- CX3CR1: Fractalkine receptor defining the microglial lineage
The embryonic origin of microglia was definitively established through fate-mapping studies using the Cx3cr1^CreER^ system, which demonstrated that adult microglia derive exclusively from yolk sac progenitors that colonize the brain rudiment before the onset of definitive hematopoiesis[@ginhoux2010].
Adult Maintenance
In the healthy adult brain, microglia maintain homeostasis through continuous surveillance of their territory[@davalos2005]. Each microglia extends highly motile processes that scan the surrounding parenchyma every few hours, enabling rapid detection of pathological changes[@nimmerjahn2005]. This surveillance function is energy-intensive and requires intact mitochondrial metabolism[@kaindlstorfer2015].
The adult microglial population turns over slowly, with an estimated half-life of several years in humans[@ru2017]. However, this turnover can be dramatically accelerated in disease states, where microglial proliferation becomes a major source of new microglia at lesion sites[@huang2018].
Regional Heterogeneity
Microglia exhibit remarkable heterogeneity across different brain regions. Transcriptomic studies have identified region-specific microglial signatures, with the hippocampus and substantia nigra showing distinct gene expression patterns[@grabert2016]. This heterogeneity likely reflects adaptations to local neuronal populations, synaptic activity, and microenvironmental cues.
| Brain Region | Key Features | Density (cells/mm³) |
|-------------|--------------|---------------------|
| Cortex | Surveillance-dominant | 5,000-10,000 |
| Hippocampus | High plasticity markers | 8,000-12,000 |
| Substantia nigra | High activation markers | 10,000-15,000 |
| Cerebellum | Unique transcriptional profile | 3,000-6,000 |
| White matter | Lower density | 2,000-5,000 |
Microglia States
Surveillance State (Homeostatic)
Resting microglia in the healthy brain maintain a characteristic phenotype:
- Morphology: Highly ramified with small cell body and long, thin processes
- Process motility: Continuous extension and retraction (2-3 μm/minute)
- TREM2/DAP12 signaling: Maintains quiescence through inhibitory signaling
- Surface markers: CX3CR1^high^, P2RY12^high^, TMEM119^high^, PU.1^positive^
- Gene expression: Low levels of immune activation genes, high levels of homeostatic genes
The homeostatic microglial transcriptome is defined by a set of "microglial signature genes" including CX3CR1, P2RY12, P2RY13, TMEM119, HEXB, and CSF1R[@butovsky2014]. These genes are downregulated upon activation and serve as markers of the surveillant state.
Key homeostatic functions include:
Synaptic surveillance: Microglial processes transiently contact synapses, particularly during development and in response to activity changes[@tremblay2010]
Cell death surveillance: Detection and clearance of apoptotic cells through phosphatidylserine recognition[@mazaheri2014]
Metabolic support: Provision of lactate and other metabolites to neurons[@matsumoto2021]The transition from surveillance to activated states is tightly regulated by pattern recognition receptors (PRRs) that detect damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)[@block2005].
Activated States
M1-like (Pro-inflammatory)
Classical activation driven by:
- [TLR4](/proteins/tlr4) recognition of damage-associated molecular patterns (DAMPs)
- IFN-γ priming from adaptive immunity
- NLRP3 inflammasome assembly
- CD40/CD40L interaction with T cells
- IFN-β autocrine signaling
Key markers: CD16, CD32, CD86, iNOS, MHC-II, CCR7, FCGR1A
Secreted factors:
- Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, IL-12, IL-18, IL-23
- Chemoattractants: CCL2, CCL5, CXCL1, CXCL10, CXCL12
- Nitric oxide (NO) via iNOS
- Reactive oxygen species (ROS) via NADPH oxidase (NOX2)
- Matrix metalloproteinases (MMP-9, MMP-12)
The classical activation cascade involves recognition of ligands by TLR4, recruitment of adaptor proteins MyD88 and TRIF, activation of NF-κB and IRF3 transcription factors, and subsequent transcription of inflammatory genes[@kawai2010]. IFN-γ synergizes with TLR signaling through STAT1 activation, amplifying the inflammatory response.
M2-like (Neuroprotective)
Alternative activation driven by:
- IL-4, IL-13, IL-10 signaling
- TGF-β production
- TREM2 activation (in AD)
- Glucocorticoid signaling
- IL-33 release from astrocytes
Key markers: CD206 (mannose receptor), Arg1, YM1, Fizz1, IL-10, TGF-β, CCL17, CCL22
Secreted factors:
- Neurotrophic factors: BDNF, NGF, GDNF, CNTF
- Anti-inflammatory cytokines: IL-10, TGF-β, IL-1RA
- Growth factors: VEGF, IGF-1
- Extracellular matrix proteins
IL-4 signaling activates STAT6, which drives expression of arginase-1 (Arg1), YM1, and Fizz1[@gordon2010]. These genes encode proteins involved in tissue repair and anti-inflammatory functions. The Arg1 enzyme competes with iNOS for L-arginine substrate, thereby reducing NO production and promoting polyamine synthesis for cell proliferation and tissue remodeling.
Disease-Associated Microglia (DAM)
A specialized microglial phenotype identified in Alzheimer's disease represents a distinct activation state[@kerenshaul2017]:
- Stage 1 (TREM2-independent): Downregulation of homeostatic genes (P2RY12, TMEM119), upregulation of Type II interferon genes
- Stage 2 (TREM2-dependent): Upregulation of lipid metabolism genes, phagocytic genes, and disease-associated genes
Key genes upregulated in DAM: APOE, TREM2, CTSD (cathepsin D), LPL (lipoprotein lipase), ITGAX (CD11C), CLEC7A[@deczkowska2020]
The transition from homeostatic microglia to DAM requires functional TREM2, and loss-of-function TREM2 variants block the DAM response, leading to reduced amyloid plaque compaction and altered plaque morphology[@wang2016].
Additional Microglial Phenotypes
Recent single-cell studies have revealed additional microglial states:
Aging-associated microglia (AAM): Upregulation of aging-related genes including Cst3, Ctsb, Ctsd[@holtman2015]
Injury-responsive microglia (IRM): Distinct transcriptional response to acute CNS injury[@zinser2022]
Lipid-loaded microglia: Foam cell-like phenotype in demyelinating diseases[@berg2022]
Proliferative response microglia (PRM): Highly proliferative cells in demyelinating lesions[@zhou2022]TREM2 Variants and Risk
TREM2 variants significantly alter microglial function and modify Alzheimer's disease risk[@guerreiro2013]:
| Variant | Effect on Function | Disease Association | Frequency |
|---------|-------------------|---------------------|-----------|
| R47H | Loss of lipid binding, reduced phagocytosis | ~3x AD risk | 0.3-0.5% |
| R62H | Reduced ligand recognition | ~2x AD risk | 0.5-0.7% |
| R33X | Truncated protein, no signaling | Nasu-Hakola disease | Rare |
| D87N | Impaired signaling | AD risk variant | 0.1% |
| T96K | Reduced function | AD risk variant | Rare |
These loss-of-function variants demonstrate that reduced microglial phagocytic capacity increases AD risk, highlighting the protective role of microglia in clearing amyloid deposits[@jonsson2013].
Neurodegenerative Disease Context
Alzheimer's Disease
Microglia in AD exhibit both protective and pathogenic roles depending on disease stage[@heneka2020]:
| Phase | TREM2 Status | Microglial Function | Therapeutic Implication |
|-------|--------------|---------------------|------------------------|
| Pre-clinical | Normal | Surveillance, Aβ clearance | Support TREM2 function |
| Early | Risk variant (R47H) | Reduced amyloid clearance | TREM2 agonists |
| Mid | TREM2 upregulation | Plaque-associated clustering | May be protective |
| Late | TREM2 dysfunction | Chronic inflammation | Anti-inflammatory |
Key interactions:
- [Amyloid-beta](/proteins/amyloid-beta) recognition via TLR4, CD14, CD36, RAGE
- [Tau](/proteins/tau) propagation via exosomes
- Complement-mediated synapse elimination (C1q, C3)
- APOE4-mediated inflammatory responses
- Neuronal loss triggers DAMP release
The microglial landscape in AD has been extensively characterized through single-cell RNA sequencing, revealing disease-specific transcriptional programs that differ from aging microglia[@mathys2019]. Apoe-expressing microglia cluster near amyloid plaques and display enhanced antigen presentation and inflammatory gene expression[@krasemann2017a].
Amyloid clearance mechanisms:
Receptor-mediated phagocytosis: TREM2, CD36, TLRs
Macroautophagy: Internalization and lysosomal degradation
Proteolytic degradation: Neprilysin, IDE
Perivascular drainage: Clearance along basement membranesTau pathology propagation:
- Microglia phagocytose tau-containing neurons
- Tau is packaged into exosomes
- Exosomal tau is released and taken up by neighboring neurons
- This spreads tau pathology throughout connected brain regions
Complement-mediated synapse loss:
- C1q localizes to synapses in early AD
- Microglia recognize C1q-tagged synapses via CR3
- Synaptic phagocytosis contributes to cognitive decline[@stephan2013]
Parkinson's Disease
Microglial activation in PD is among the earliest pathological changes[@block2007]:
- Substantia nigra pars compacta shows highest density of activated microglia
- Chronic activation precedes motor symptoms by years
- Postmortem studies show MHC-II positive microglia in >90% of PD cases
- Activation correlates with dopaminergic neuron loss
Triggers:
- [α-Synuclein](/proteins/alpha-synuclein) aggregates (via TLR2, TLR4, CD36)
- Mitochondrial DAMPs from dying dopaminergic neurons
- Environmental toxins (MPTP, rotenone, paraquat)
- Gut-derived microbial molecules (via vagus nerve)
- Neuromelanin release from dying neurons
Neuroinflammatory cascade:
α-Synuclein oligomers activate TLR2/4 on microglia
MyD88-dependent signaling activates NF-κB
Pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6)
NADPH oxidase generates ROS
Cytokines cause dopaminergic neuron toxicity
Dying neurons release more DAMPs, creating feedback loopGenetic risk factors:
- LRRK2 G2019S increases microglial inflammation[@moehle2012]
- Parkin and PINK1 mutations affect mitophagy and DAMP release
- GBA variants enhance microglial activation[@chahine2013]
Amyotrophic Lateral Sclerosis
Microglia in ALS demonstrate rapid activation concurrent with motor neuron loss[@appel2010]:
- Mutant SOD1 triggers non-cell-autonomous toxicity
- P2X7 receptor mediates inflammatory cascade
- Proliferating microglia surround motor neurons
- MCP-1 (CCL2) drives monocyte recruitment
Microglial phenotypes in ALS:
- M1-like markers: iNOS, NOX2, IL-1β (disease progression)
- M2-like markers: YM1, CD206 (early disease)
- Transition from neuroprotective to neurotoxic with disease progression
SOD1 models:
- Mutant SOD1G93A mice show microglial activation at disease onset
- Selective removal of mutant SOD1 from microglia delays disease
- NF-κB activation in microglia drives progression[@frakes2014]
Multiple Sclerosis
Microglia play complex roles in demyelination and remyelination[@lassmann2021]:
- Actively phagocytose myelin debris (beneficial for remyelination)
- Present antigens to T cells (pathogenic)
- Secrete inflammatory cytokines that damage oligodendrocytes
- Support remyelination through growth factor secretion
- Form lesions with distinct microglial subpopulations
Lesion stages:
Pre-active lesions: Microglial activation without demyelination
Active lesions: Inflammatory demyelination with macrophage infiltration
Shadow lesions: Remyelination with reduced microglia
Chronic lesions: Inactive microglia, persistent demyelinationSignaling Pathways
NF-κB Pathway
The primary driver of pro-inflammatory gene expression:
TLR4 activation → MyD88 → IRAK4/1 → TRAF6 → IKK → IκB degradation
↓
NF-κB translocation
↓
Pro-inflammatory gene transcription
Key targets:
- Cytokines: TNF-α, IL-1β, IL-6, IL-12
- Chemokines: CCL2, CXCL10
- Enzymes: iNOS, COX-2
- Surface molecules: MHC-II, adhesion molecules
- Anti-apoptotic proteins: Bcl-2, Bcl-xL
NLRP3 Inflammasome
Intracellular sensor for DAMPs that amplifies inflammation[@heneka2013]:
DAMP recognition → ASC recruitment → Pro-caspase-1 activation
↓
Pro-IL-1β + pro-IL-18 cleavage
↓
IL-1β/IL-18 release
In AD, Aβ activates NLRP3, creating a chronic inflammatory loop[@masters2020]. NLRP3 deficiency in mouse models reduces amyloid pathology and improves cognitive function[@coll2015]. The inflammasome requires two signals: priming (NF-κB-dependent) and activation (ROS, potassium efflux, lysosomal damage).
TREM2 Signaling
Myeloid cell receptor for lipid metabolism and phagocytosis[@painter2015]:
- Activating mutations: Gain of function in Alzheimer's (R47H, R62H)
- Ligands: Lipids, APOE, amyloid plaques, bacterial products, apoptotic cells
- Adaptor protein: DAP12 (TYROBP)
- Downstream pathways: SYK, PI3K, MAPK, GSK3β
TREM2 signaling regulates:
- Phagocytosis of Aβ, apoptotic cells, myelin debris
- Lipid metabolism and cholesterol efflux
- Microglial survival and proliferation
- Inflammatory cytokine production
- Metabolic reprogramming
cGAS-STING Pathway
DNA sensing pathway increasingly implicated in neurodegeneration[@gulen2020]:
- Mitochondrial DNA released from damaged neurons
- Cytosolic DNA accumulation in aging microglia
- cGAMP production activates STING
- Type I interferon response induction
- Chronic inflammation in AD and PD
MAPK Pathways
p38 MAPK and JNK pathways mediate stress responses:
- p38α regulates TNF-α, IL-1β production
- JNK controls apoptosis and cytokine expression
- ERK pathway involved in proliferation
- Therapeutic targeting with kinase inhibitors
Morphological Changes
Microglia undergo characteristic morphological transformations:
Surveillant: Small soma, long thin processes, complex arborization
Reactive: Enlarged soma, thicker processes, reduced branching
Amoeboid: Large soma, few short processes (fully activated)
Gitter cells: Large vacuolated cytoplasm (engulfing debris)These morphological changes correlate with functional states and can be visualized using Iba1, TMEM119, or P2RY12 immunostaining[@ayata2018]. Three-dimensional reconstruction reveals process complexity decreases with activation while soma size increases.
Therapeutic Implications
Targeting Microglial Proliferation
| Approach | Target | Agent | Status |
|----------|--------|-------|--------|
| CSF1R antagonism | Reduce microglial numbers | PLX3397 | Preclinical |
| CSF1R antagonism | Reduce microglial numbers | PLX5622 | Preclinical |
| CSF1R antagonism | Reduce microglial numbers | BLZ945 | Phase 1/2 |
| CSF1R antagonism | Reduce microglial numbers | Tiludronate | Phase 2 |
PLX5622 treatment in 5xFAD mice reduces plaque-associated microglia and improves cognitive function[@spangenberg2019]. However, complete microglial depletion leads to neuronal damage, suggesting a balance is needed.
Immunomodulatory Approaches
| Approach | Target | Agent | Status |
|----------|--------|-------|--------|
| NLRP3 inhibition | Inflammasome | MCC950 | Preclinical |
| TREM2 agonism | Phagocytosis | Anti-TREM2 antibodies | Phase 1/2 |
| CX3CR1 antagonism | Recruitment | AZD4619 | Phase 1 |
| P2X7 antagonism | ATP signaling | CE-224,535 | Phase 2 (failed) |
| CD33 antagonism | Phagocytosis inhibition | Anti-CD33 antibodies | Preclinical |
Repositioned Drugs
- Minocycline: Broad anti-inflammatory, Phase 3 failed in ALS[@gordon2007]
- Tiludronate: CSF1R inhibitor, tested in AD
- Losmapimod: p38 MAPK inhibitor, neuroinflammation
- Masitinib: Tyrosine kinase inhibitor, ALS Phase 3[@piette2021]
- Dextromethorphan: NMDA antagonist, microglial activation
Emerging Strategies
- Microglia replacement: Bone marrow transplantation approaches
- Gene therapy: TREM2 expression vectors
- Small molecules: Selective CSF1R agonists/antagonists
- Biologics: Anti-CD33 antibodies, anti-TREM2 antibodies
- MicroRNA therapy: Modulating microglial gene expression
Biomarkers
Microglial activation can be monitored through:
- PET imaging: TSPO ligands (e.g., [^11C]PK11195, [^18F]DPA-714)[@kreisl2013]
- CSF markers: YKL-40 (chitinase-3-like protein 1), sTREM2[@suarezfartinez2018]
- Blood markers: MCP-1 (CCL2), IL-6, TNF-α
- Structural MRI: Regional brain atrophy patterns
TSPO PET studies demonstrate increased microglial activation in AD, PD, and ALS patients, correlating with disease severity[@cagnin2001]. Second-generation TSPO ligands show improved specificity.
Microglial Activation States
Mermaid diagram (expand to render)
See Also
- [AD](/diseases/alzheimers-disease)
- [PD](/diseases/parkinsons-disease)
- [ALS](/diseases/als)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [TLR4](/proteins/tlr4)
- [TREM2](/proteins/trem2)
- [Amyloid-beta](/proteins/amyloid-beta)
- [Tau](/proteins/tau)
- [α-Synuclein](/proteins/alpha-synuclein)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
- [Complement System](/mechanisms/complement-system)
External Links
- [PubMed: Microglia Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=microglia+neurodegeneration)
- [KEGG Pathways - Microglial Phagocytosis](https://www.genome.jp/kegg/pathway.html)
- [Allen Brain Atlas: Microglia](https://mouse.brain-map.org/)
Species-Specific Considerations
Human vs. Mouse Microglia
Translational research requires understanding species differences:
- Human microglia express unique genes (APOE, TREM2 variants have different frequencies)
- Mouse models do not fully recapitulate human microglial responses
- In vitro systems differ significantly from in vivo
- 3D brain organoids provide human-relevant models
Aging Microglia
Aging is associated with microglial dysfunction:
- Reduced process motility and surveillance
- Increased baseline inflammation ("inflammaging")
- Accumulation of lipofuscin
- Impaired phagocytosis
- Altered responses to injury
Aging microglia show a distinct transcriptional signature including upregulated stress response genes, complement components, and lysosomal genes[@streit2014].
[@streit2014]: [Streit et al., Microglia and aging (2014)](https://pubmed.ncbi.nlm.nih.gov/25027553/)
References
[Heneka et al., Neuroinflammation in Alzheimer's disease (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26362584/)
[Unknown, Prinz & Priller, Microglia in the CNS (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25283771/)
[Ginhoux et al., Origin and differentiation of microglia (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23325224/)
[Ajami et al., Local self-renewal of microglia (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17934063/)
[Elmore et al., CSF1R signaling regulates microglia (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25599329/)
[Unknown, Ransohoff, A polarizing question (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27268866/)
[Krasemann et al., TREM2-Deficient Microglia (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28257655/)
[Alliot et al., Microglia derive from yolk sac (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10518543/)
[Kierdorf et al., Microglia development (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23552976/)
[Schulz et al., PU.1 is essential for microglia (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22740213/)
[Ginhoux et al., Fate mapping microglia (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20063755/)
[Davalos et al., ATP-induced chemotaxis (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/16014714/)
[Nimmerjahn et al., Resting microglia in vivo (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/16014714/)
[Kaindlstorfer et al., Microglial energy metabolism (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25601764/)
[Réu et al., Lifespan of human microglia (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28957867/)
[Huang et al., Microglial proliferation in disease (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29429850/)
[Grabert et al., Regional microglia diversity (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27152174/)
[Butovsky et al., Microglial signature (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24305793/)
[Tremblay et al., Microglial synaptic contact (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20920788/)
[Mazaheri et al., Apoptotic cell clearance (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24828042/)
[Matsumoto et al., Microglial metabolic support (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33521863/)
[Unknown, Block & Hong, Microglia and neurodegeneration (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15834930/)
[Unknown, Kawai & Akira, TLR signaling (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20616806/)
[Unknown, Gordon & Martinez, Alternative activation (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20802328/)
[Keren-Shaul et al., DAM microglia (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28602351/)
[Deczkowska et al., Disease-associated microglia (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32109291/)
[Wang et al., TREM2 and plaque morphology (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26744410/)
[Holtman et al., Aging microglia (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26468524/)
[Zinser et al., Injury-responsive microglia (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35135972/)
[Berg et al., Lipid-loaded microglia (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35618625/)
[Zhou et al., Proliferative response microglia (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35012831/)
[Guerreiro et al., TREM2 variants in AD (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23530040/)
[Jonsson et al., TREM2 and AD risk (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23563579/)
[Heneka et al., microglia in AD (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32780987/)
[Mathys et al., Single-cell analysis of AD (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31042697/)
[Krasemann et al., TREM2-APOE pathway (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28257655/)
[Stephan et al., Complement and synapse elimination (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24238042/)
[Block et al., Microglia and Parkinson's disease (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17617661/)
[Moehle et al., LRRK2 and neuroinflammation (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22426079/)
[Chahine et al., GBA and Parkinson's disease (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24323332/)
[Appel et al., Non-cell-autonomous toxicity in ALS (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20150125/)
[Frakes et al., Microglia in ALS progression (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24552650/)
[Lassmann et al., Microglia in multiple sclerosis (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33587275/)
[Heneka et al., NLRP3 inflammasome in AD (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23530142/)
[Masters et al., Aβ activates NLRP3 (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32877965/)
[Coll et al., NLRP3 deficiency in AD (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26655582/)
[Painter et al., TREM2 structure and function (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25614319/)
[Gulen et al., cGAS-STING in neurodegeneration (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32720960/)
[Ayata et al., Microglial morphology (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29320725/)
[Spangenberg et al., PLX5622 reduces microglia (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31737537/)
[Gordon et al., Minocycline in ALS (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17428009/)
[Piette et al., Masitinib in ALS (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33577223/)
[Kreisl et al., TSPO PET in neurodegeneration (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23624154/)
[Suarez-Fartinez et al., sTREM2 as biomarker (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29342113/)
[Cagnin et al., In vivo microglial activation (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11231007/)
[Streit et al., Microglia and aging (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25027553/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Phase-Separated Organelle Targeting](/hypothesis/h-ec731b7a) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: G3BP1
- [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
- [Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA
- [Metabolic Circuit Breaker via Lipid Droplet Modulation](/hypothesis/h-3d993b5d) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: PLIN2
- [Temporal Decoupling via Circadian Clock Reset](/hypothesis/h-019ad538) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: CLOCK
- [Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: CX3CR1
- [Synthetic Biology Rewiring via Orthogonal Receptors](/hypothesis/h-e3506e5a) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: CNO
- [Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics](/hypothesis/h-513a633f) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: ANXA1
Related Analyses:
- [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-01-gap-001) 🔄
- [Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119) 🔄
- [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-02-gap-001) 🔄
- [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Microglia Activation Mechanism discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)